Cargando…

Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation

INTRODUCTION: Chondrosarcoma is a malignant cartilage-forming bone tumour in which mutations in IDH1 and IDH2 frequently occur. Previous studies suggest an increased dependency on glutaminolysis in IDH1/2 mutant cells, which resulted in clinical trials with the drugs CB-839, metformin and chloroquin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peterse, Elisabeth F. P., Niessen, Bertine, Addie, Ruben D., de Jong, Yvonne, Cleven, Arjen H. G., Kruisselbrink, Alwine B., van den Akker, Brendy E. W. M., Molenaar, Remco J., Cleton-Jansen, Anne-Marie, Bovée, Judith V. M. G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931088/ https://www.ncbi.nlm.nih.gov/pubmed/29576625 http://dx.doi.org/10.1038/s41416-018-0050-9

Ejemplares similares

Targeting the NAD Salvage Synthesis Pathway as a Novel Therapeutic Strategy for Osteosarcomas with Low NAPRT Expression
por: Franceschini, Natasja, et al.
Publicado: (2021)

Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status
por: Venneker, Sanne, et al.
Publicado: (2019)

Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway
por: Addie, Ruben D., et al.
Publicado: (2019)

Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma
por: Venneker, Sanne, et al.
Publicado: (2020)

No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone
por: Peterse, Elisabeth F. P., et al.
Publicado: (2016)

IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas
por: Cleven, Arjen H. G., et al.
Publicado: (2017)

BMP and TGFbeta pathways in human central chondrosarcoma: enhanced endoglin and Smad 1 signaling in high grade tumors
por: Boeuf, Stephane, et al.
Publicado: (2012)

IDH Mutations in Chondrosarcoma: Case Closed or Not?
por: Venneker, Sanne, et al.
Publicado: (2023)

Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes
por: de Jong, Yvonne, et al.
Publicado: (2019)

Targeting survivin as a potential new treatment for chondrosarcoma of bone
por: de Jong, Y, et al.
Publicado: (2016)

SUMOylation Is Associated with Aggressive Behavior in Chondrosarcoma of Bone
por: Kroonen, Jessie S., et al.
Publicado: (2021)

Conventional chondrosarcoma with focal clear cell change: a clinicopathological and molecular analysis
por: Lam, Suk Wai, et al.
Publicado: (2019)

Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma
por: de Jong, Yvonne, et al.
Publicado: (2018)

Selection of Effective Therapies Using Three-Dimensional in vitro Modeling of Chondrosarcoma
por: Palubeckaitė, Ieva, et al.
Publicado: (2020)

A screening-based approach identifies cell cycle regulators AURKA, CHK1 and PLK1 as targetable regulators of chondrosarcoma cell survival
por: de Jong, Yvonne, et al.
Publicado: (2019)

Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines
por: Suijker, Johnny, et al.
Publicado: (2015)

Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy
por: Sundara, Yayan T., et al.
Publicado: (2016)

Expanding the Spectrum of EWSR1-NFATC2-rearranged Benign Tumors: A Common Genomic Abnormality in Vascular Malformation/Hemangioma and Simple Bone Cyst
por: Ong, Sheena L.M., et al.
Publicado: (2021)

The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo
por: Suijker, Johnny, et al.
Publicado: (2015)

A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target
por: Franceschini, Natasja, et al.
Publicado: (2021)

Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro
por: Schrage, Yvonne M, et al.
Publicado: (2009)

Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo
por: Meijer, Danielle, et al.
Publicado: (2011)

Transformed Canine and Murine Mesenchymal Stem Cells as a Model for Sarcoma with Complex Genomics
por: Franceschini, Natasja, et al.
Publicado: (2021)

NTRK fusions are extremely rare in bone tumours
por: Lam, Suk Wai, et al.
Publicado: (2021)

IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma
por: Lugowska, Iwona, et al.
Publicado: (2018)

IMMUNOHISTOCHEMICAL ANALYSIS BY KI67 AND IDH1 IN PATIENTS WITH CHONDROSARCOMA
por: RIBEIRO, MARCELO BARBOSA, et al.
Publicado: (2023)

IDH1/2 Mutations in Cancer Stem Cells and Their Implications for Differentiation Therapy
por: Molenaar, Remco J., et al.
Publicado: (2021)

Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth
por: Li, Luyuan, et al.
Publicado: (2020)

Mutant IDH and non-mutant chondrosarcomas display distinct cellular metabolomes
por: Pathmanapan, Sinthu, et al.
Publicado: (2021)

Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma
por: Nakagawa, Makoto, et al.
Publicado: (2022)

IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma
por: Kuijjer, Marieke L, et al.
Publicado: (2013)

Glutaminolysis gets the spotlight in cancer
por: Herranz, Daniel
Publicado: (2016)

Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta‐analysis
por: Vuong, Huy Gia, et al.
Publicado: (2021)

Clonality analysis and IDH1 and IDH2 mutation detection in both components of dedifferentiated chondrosarcoma, implicated its monoclonal origin
por: Yang, Tingting, et al.
Publicado: (2020)

Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone
por: van Oosterwijk, Jolieke G, et al.
Publicado: (2012)

A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors
por: Khurshed, Mohammed, et al.
Publicado: (2021)

Glutaminolysis feeds mTORC1
por: Durán, Raúl V., et al.
Publicado: (2012)

Governing glutaminolysis by regulation of glutaminase succinylation
por: Ma, Qingxia, et al.
Publicado: (2021)

In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma
por: Khurshed, Mohammed, et al.
Publicado: (2017)

Energy Metabolism in IDH1 Wild-Type and IDH1-Mutated Glioblastoma Stem Cells: A Novel Target for Therapy?
por: van Noorden, Cornelis J.F., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_snukoq7300gd7g8lbej3acdqo1